Innovent Biologics has announced that the first patient has been successfully dosed in a Phase IIa clinical study of IBI306, a recombinant anti-proprotein convertase substilisin/kexin type 9 (anti-PCSK9) monoclonal antibody, to treat hypercholesterolemia.

The placebo-controlled, double-blind, randomised, multiple ascending dose clinical trial is being conducted in China.

Under repeatedly different doses, the trial will evaluate the efficacy, tolerability, safety, as well as pharmacodynamics (PD) and pharmacokinetics (PK) profiles of IBI306.

“We hope IBI30, a recombinant fully human monoclonal antibody, will provide a better treatment option for patients with cardiovascular diseases.”

IBI306 binds to proprotein convertase substilisin/kexin type 9 (PCSK9) molecules. Furthermore, by reducing PCSK9-mediated low-density lipoprotein (LDL) receptor endocytosis, IBI306cuts down low-density lipoprotein cholesterol (LDL-C) levels.

Under the Phase I study, IBI306 preliminarily indicated good tolerability and acceptable safety profiles and offered prolonged dose-dependent reduction of LDL-C levels in healthy subjects.

The Phase IIa study will see enrollment of 60 patients with hypercholesterolemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Peking University First Hospital director of the department of pharmacy Yimin Cui said: “IBI306 was well tolerated and had an acceptable safety profile in the Phase I trial in healthy subjects. Furthermore, it reduces blood lipid levels in a dose-dependent manner. One unique feature of IBI306 is it can be potentially dosed with a long dosing interval. The results are encouraging.”

Innovent chairman, founder and CEO Michael Yu said: “IBI306 is a Category I biological innovative drug candidate developed by Innovent for the treatment of hypercholesterolemia. It has shown acceptable safety and good tolerability profile in Phase Ia study. We are looking forward to rapidly moving IBI306 into late-stage clinical development. We hope IBI306 can eventually benefit patients with cardiovascular diseases.”

Hypercholesterolemia is considered to be a grave issue in China as a result of unhealthy diet, lifestyles and aging population.

Dyslipidemia caused due to hypercholesterolemia is considered to be a major risk factor for cardiovascular mortality.